![Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments](https://www.mdpi.com/diseases/diseases-11-00148/article_deploy/html/images/diseases-11-00148-g001.png)
Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments
![Cancers | Free Full-Text | Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies Cancers | Free Full-Text | Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies](https://www.mdpi.com/cancers/cancers-14-01732/article_deploy/html/images/cancers-14-01732-g001.png)
Cancers | Free Full-Text | Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies
![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2119136921/2089647169/gr1.gif)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
![PANDA study demonstrates progression-free survival gain for FOLFOX + panitumumab and 5FU / LV + first-line panitumumab to RAS-BRAF wild-type elderly metastatic colorectal cancer patients - Onco Americas PANDA study demonstrates progression-free survival gain for FOLFOX + panitumumab and 5FU / LV + first-line panitumumab to RAS-BRAF wild-type elderly metastatic colorectal cancer patients - Onco Americas](https://www.oncoamericas.com/wp-content/uploads/2020/06/INGLES_GASTROINTESTINAL_First-line_FOLFOX_plus_panitumumab_PANDA_Noticias-Retangular.png)
PANDA study demonstrates progression-free survival gain for FOLFOX + panitumumab and 5FU / LV + first-line panitumumab to RAS-BRAF wild-type elderly metastatic colorectal cancer patients - Onco Americas
![Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results - ScienceDirect Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419351312-gr1.jpg)
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results - ScienceDirect
![Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-020-0116-z/MediaObjects/41392_2020_116_Fig1_HTML.png)
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. | Semantic Scholar Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7da083ce90bf4df8eecd9d8feffbdd53d2c67d52/6-Figure3-1.png)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. | Semantic Scholar
![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - ScienceDirect Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204513701542-gr3.jpg)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - ScienceDirect
![Update on the management of elderly patients with colorectal cancer | Clinical and Translational Oncology Update on the management of elderly patients with colorectal cancer | Clinical and Translational Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12094-023-03243-0/MediaObjects/12094_2023_3243_Fig1_HTML.png)
Update on the management of elderly patients with colorectal cancer | Clinical and Translational Oncology
![Cancers | Free Full-Text | Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study Cancers | Free Full-Text | Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study](https://pub.mdpi-res.com/cancers/cancers-14-05208/article_deploy/html/images/cancers-14-05208-g001.png?1666615899)